Mobile Covid-19 testing lab launched for Northeast starting Mizoram

Beginning with Mizoram, the Centre on Thursday launched a Mobile Covid testing facility for Northeast India.

covid test jammu
A health worker in Jammu takes her swab sample for a Covid-19 test on January 16, 2022. (PTI Photo)
IANS New Delhi
2 min read Last Updated : Jan 21 2022 | 8:58 AM IST

Beginning with Mizoram, the Centre on Thursday launched a Mobile Covid testing facility -- a first of its kind Mobile Diagnostic Laboratory (I-LAB) capable of performing both RT-PCR and ELISA tests -- for Northeast India.

The mobile lab has bio-safety facility and is capable of performing both RT-PCR and ELISA tests. It can also be utilised for testing other infectious diseases like TB, HIV, and therefore will remain relevant even in post-Covid times.

The Mobile Lab Technology will be rolled out gradually in other states of the Northeast as the region has unique climatic and topographical conditions.

It has been developed with support from the Department of Biotechnology (DBT) under the Ministry of Science & Technology, government of India, and is meant to provide Covid testing access to rural and remote parts of Northeast, a release from the Ministry said.

Union Minister of State for Science & Technology, Jitendra Singh, launched the mobile testing facility with Mizoram Chief Minister Pu Zoramthanga joining the ceremony online.

Exuding confidence that India will emerge triumphant from the current pandemic situation, Singh called for linking the I-LAB with a tele-consultation facility in accordance with disease profile of the population of the northeastern region.

He informed that tests like mammography and vision-testing can be added to the mobile laboratory which will prove hugely beneficial for the people of the region.

Singh said that ever since Narendra Modi took over as the Prime Minister, he has accorded special priority to the development of the Northeast, adding that this facility is a testimony of that commitment.

Acknowledging the efforts made by the AMTZ (Andhra Pradesh MedTech Zone) team for building the innovative facility, Singh said the DBT has also established manufacturing facility in AMTZ for indigenously manufacturing various healthcare technologies, which are hugely imported, thereby helping us realise the vision of 'Make-in India, Make for India'.

Speaking on the occasion, Zoramthanga said that this will help bridge the gap in Covid testing in the border districts and remote areas lacking in RT-PCR testing facilities.

--IANS

niv/arm

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsMizoramNortheast Indiahealth

First Published: Jan 21 2022 | 8:58 AM IST

Next Story